{"title":"evinacumab -治疗纯合子家族性高胆固醇血症","authors":"A. Basaria, Ismat Fatima, N. Raufi","doi":"10.1097/GH9.0000000000000254","DOIUrl":null,"url":null,"abstract":"A rare life-threatening condition known as homozygous familial hypercholesterolemia (HoFH) is characterized by markedly elevated levels of low-density lipoprotein cholesterol (LDL-C) in the blood and accelerated, premature atherosclerotic cardiovascular disease (ACVD) [1] . It is clinically characterized by extensive xanthomas, marked premature and progressive ACVD","PeriodicalId":306111,"journal":{"name":"International Journal of Surgery: Global Health","volume":"8 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2023-08-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Evinacumab—a treatment for homozygous familial hypercholesterolemia\",\"authors\":\"A. Basaria, Ismat Fatima, N. Raufi\",\"doi\":\"10.1097/GH9.0000000000000254\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"A rare life-threatening condition known as homozygous familial hypercholesterolemia (HoFH) is characterized by markedly elevated levels of low-density lipoprotein cholesterol (LDL-C) in the blood and accelerated, premature atherosclerotic cardiovascular disease (ACVD) [1] . It is clinically characterized by extensive xanthomas, marked premature and progressive ACVD\",\"PeriodicalId\":306111,\"journal\":{\"name\":\"International Journal of Surgery: Global Health\",\"volume\":\"8 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-08-25\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International Journal of Surgery: Global Health\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1097/GH9.0000000000000254\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Surgery: Global Health","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1097/GH9.0000000000000254","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Evinacumab—a treatment for homozygous familial hypercholesterolemia
A rare life-threatening condition known as homozygous familial hypercholesterolemia (HoFH) is characterized by markedly elevated levels of low-density lipoprotein cholesterol (LDL-C) in the blood and accelerated, premature atherosclerotic cardiovascular disease (ACVD) [1] . It is clinically characterized by extensive xanthomas, marked premature and progressive ACVD
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
